PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9808873-11 1998 Differences in BTG levels between aspirin-treated and aspirin-untreated patients became significant at 48 hours after thrombolysis in both groups. Aspirin 34-41 pro-platelet basic protein Homo sapiens 15-18 9808873-11 1998 Differences in BTG levels between aspirin-treated and aspirin-untreated patients became significant at 48 hours after thrombolysis in both groups. Aspirin 54-61 pro-platelet basic protein Homo sapiens 15-18 8883266-5 1996 Treatment of erythromelalgia with aspirin resulted in disappearance of erythromelalgic signs and symptoms, which was paralleled by a significant decrease of beta-TG and TM levels. Aspirin 34-41 pro-platelet basic protein Homo sapiens 157-164 10608053-11 1998 Patients treated with aspirin showed lower levels of BTG only from the 48th hour after thrombolysis in both groups. Aspirin 22-29 pro-platelet basic protein Homo sapiens 53-56 10608053-20 1998 Treatment with aspirin reduced beta-thromboglobulin plasma levels only at 48th hour in both groups. Aspirin 15-22 pro-platelet basic protein Homo sapiens 31-51 8868511-7 1996 Additionally, in five YSMI patients the influence of prolonged aspirin administration (0.3g daily for more than 30 days) on the Fraxiparine mobilsable pool of PF4 and beta-thromboglobulin (beta-TG) concentration in the plasma was determined after injection of 180 IC anti-Xa U/kg b.w. Aspirin 63-70 pro-platelet basic protein Homo sapiens 167-187 8148359-10 1994 The plasma levels of FPA and beta-TG were slightly lower in nonsmokers and after aspirin ingestion. Aspirin 81-88 pro-platelet basic protein Homo sapiens 29-36 7946179-10 1994 Addition of aspirin to nitrendipine produced a significant decrease and flattening of the beta-TG curve, whereas the combination of aspirin and isradipine was accompanied by a partial increase in plasma beta-TG levels. Aspirin 12-19 pro-platelet basic protein Homo sapiens 90-97 7946179-10 1994 Addition of aspirin to nitrendipine produced a significant decrease and flattening of the beta-TG curve, whereas the combination of aspirin and isradipine was accompanied by a partial increase in plasma beta-TG levels. Aspirin 132-139 pro-platelet basic protein Homo sapiens 203-210 2791406-8 1989 On the contrary, aspirin with ticlopidine reduced TXB2 as well as beta TG and PF4. Aspirin 17-24 pro-platelet basic protein Homo sapiens 66-73 8205303-9 1994 Aspirin added to nitrendipine led to a further significant decrease in beta-TG levels whereas its addition to isradipine was accompanied by a partial increase in plasma beta-TG. Aspirin 0-7 pro-platelet basic protein Homo sapiens 71-78 21043721-5 1994 While 50% of the secretion of beta-TG persisted in spite of aspirin treatment, secretion of (14)C-serotonin was completely abolished. Aspirin 60-67 pro-platelet basic protein Homo sapiens 30-37 21043721-7 1994 Platelet secretion of beta-TG and (14)C-serotonin induced by a high dose of collagen was significantly reduced by aspirin, while a low dose of collagen induced a cyclooxygenase-independent secretion of beta-TG and (14)C-serotonin. Aspirin 114-121 pro-platelet basic protein Homo sapiens 22-29 8466742-9 1993 Aspirin added to nitrendipine produced a significant decrease in beta-TG levels whereas isradipine plus aspirin was accompanied by a partial increase in beta-TG. Aspirin 0-7 pro-platelet basic protein Homo sapiens 65-72 8466742-9 1993 Aspirin added to nitrendipine produced a significant decrease in beta-TG levels whereas isradipine plus aspirin was accompanied by a partial increase in beta-TG. Aspirin 104-111 pro-platelet basic protein Homo sapiens 153-160 8342880-7 1993 In conclusion low-dose ASA inhibits collagen-induced release of both beta-TG and PDGF in PRP and TxB2-synthesis in PRP and serum. Aspirin 23-26 pro-platelet basic protein Homo sapiens 69-76 2147914-2 1990 Ticlopidine and aspirin/dipyridamole, but not xanthinol nicotinate, improved platelet aggregation, reduced beta-thromboglobulin, platelet factor IV and fibrinopeptide A concentrations, and increased antithrombin III concentrations and red blood cell filterability. Aspirin 16-23 pro-platelet basic protein Homo sapiens 107-127 2139442-0 1990 Increased plasma beta-thromboglobulin in patients with coronary artery vein graft occlusion: response to low dose aspirin. Aspirin 114-121 pro-platelet basic protein Homo sapiens 17-37 2139442-3 1990 Serial beta-thromboglobulin levels were measured in 105 patients randomized to receive aspirin (324 mg/day) or placebo beginning within 1 h after surgery. Aspirin 87-94 pro-platelet basic protein Homo sapiens 7-27 2139442-9 1990 The reduction in beta-thromboglobulin concentration from the preoperative level to 12 months postoperatively was greater in the aspirin-treated group (p less than 0.001). Aspirin 128-135 pro-platelet basic protein Homo sapiens 17-37 2139442-10 1990 Multivariate logistic regression analysis demonstrated a significant association between preoperative beta-thromboglobulin concentration and graft occlusion (p less than 0.02), and aspirin treatment was effective in preventing occlusion when adjusted for the preoperative beta-thromboglobulin level (p less than 0.005). Aspirin 181-188 pro-platelet basic protein Homo sapiens 272-292 2960124-4 1987 Administration to the patients of ASA, at the dose that does not affect prostacyclin production, determined a decrease of beta-TG in 77% of the patients. Aspirin 34-37 pro-platelet basic protein Homo sapiens 122-129 6230778-8 1984 Administration of aspirin to the patients affected by common and classic migraine caused a decrease in plasma beta-TG and PF4 concentration. Aspirin 18-25 pro-platelet basic protein Homo sapiens 110-117 2437338-3 1987 In the first patient, although aspirin prevented both in vitro heparin-induced platelet aggregation (70% without and 7.5% with aspirin) and 14C serotonin release (48% without and 0% with aspirin), intraoperative administration of heparin resulted in an increase in plasma levels of platelet factor 4 from 8 to 260 ng/ml and beta-thromboglobulin levels from 29 to 39 ng/ml. Aspirin 31-38 pro-platelet basic protein Homo sapiens 324-344 2954264-6 1987 Therapy with ASA caused a significant decrease in the plasma levels of beta-TG (median: 30.4----26.6 ng/ml, p less than 0.001) and PF 4 (2.95----2.2 ng/ml, p less than 0.01). Aspirin 13-16 pro-platelet basic protein Homo sapiens 71-78 2934863-5 1985 The ADP-removal and ASA-ingestion also strongly inhibited the beta-TG release. Aspirin 20-23 pro-platelet basic protein Homo sapiens 62-69 3535158-3 1986 Aspirin was able to reduce the postoperative increase in circulating platelet aggregates, platelet factor 4 and beta-thromboglobulin observed in control group. Aspirin 0-7 pro-platelet basic protein Homo sapiens 112-132 3161220-10 1985 Moreover, beta-TG levels in patients on chronic ASA therapy at the time of stroke did not differ from those in patients of the same diagnostic categories not taking aspirin. Aspirin 48-51 pro-platelet basic protein Homo sapiens 10-17 3160472-4 1985 Administration of aspirin (ASA) was more effective than flunarizine in inducing a decrease in beta-TG and PF4 plasma levels in migraineurs. Aspirin 18-25 pro-platelet basic protein Homo sapiens 94-101 3160472-4 1985 Administration of aspirin (ASA) was more effective than flunarizine in inducing a decrease in beta-TG and PF4 plasma levels in migraineurs. Aspirin 27-30 pro-platelet basic protein Homo sapiens 94-101 6184841-0 1982 Effect of aspirin on platelet 5-hydroxytryptamine and beta-thromboglobulin plasma levels in patients with myeloproliferative diseases. Aspirin 10-17 pro-platelet basic protein Homo sapiens 54-74 6197783-7 1983 In many patients with ischemic or obstructive cerebro-vascular diseases treated with anti-platelet drugs such as Aspirin, Dipyridamole, Bencyclane or Ticlopidine, a significant fall in plasma concentration of beta-TG was chronologically demonstrated. Aspirin 113-120 pro-platelet basic protein Homo sapiens 209-216 24433129-0 2014 Beta-thromboglobulin as a marker of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting following aspirin discontinuation. Aspirin 137-144 pro-platelet basic protein Homo sapiens 0-20 6215739-6 1982 Aspirin given to six patients at a dose sufficient to eliminate the secondary phase of ADP-induced platelet aggregation reduced mean beta TG and the mean beta TG: whole blood platelet count ratio but did not alter mean FpA and B beta 1-42. Aspirin 0-7 pro-platelet basic protein Homo sapiens 133-140 6215739-6 1982 Aspirin given to six patients at a dose sufficient to eliminate the secondary phase of ADP-induced platelet aggregation reduced mean beta TG and the mean beta TG: whole blood platelet count ratio but did not alter mean FpA and B beta 1-42. Aspirin 0-7 pro-platelet basic protein Homo sapiens 154-161 24433129-7 2014 Postoperatively, after administration of 4-6 doses of aspirin, beta-TG increased by 16.7% and 8-iso-PGF2alpha increased by 17.2% 5-7 days after surgery (p = 0.005 and p < 0.001, respectively). Aspirin 54-61 pro-platelet basic protein Homo sapiens 63-70 6176160-6 1982 Significant reductions in circulating platelet aggregates and beta-thromboglobulin levels were achieved in 10 patients by dipyridamole and aspirin therapy. Aspirin 139-146 pro-platelet basic protein Homo sapiens 62-82 162473-4 1979 This increased aggregatability (not hyperglycemia determined) is reversed by a few days of insulin treatment or by dipyrimadole (alone or with synergistic acetyl salicylic acid): (2) Beta-thromboglobulin is released from platelets and is increased in venesected blood from diabetics after a standardized procedure (no prostaglandin E1 in anticoagulant) with final radioimmunoassay. Aspirin 155-176 pro-platelet basic protein Homo sapiens 183-203 26663880-11 2016 RESULTS: Clopidogrel plus aspirin and clopidogrel plus placebo reduced beta-TG by a GMR of 0.51 (0.42-0.63) and 0.54 (0.46-0.64) at 2 h. Ticagrelor plus aspirin and ticagrelor plus placebo decreased beta-TG by a GMR of 0.38 (0.26-0.57) and 0.47 (0.31-0.72). Aspirin 26-33 pro-platelet basic protein Homo sapiens 71-78 17966595-11 2007 Independent predictors of beta-thromboglobulin were a male gender and aspirin use cessation (beta = 0.46; p = 0.01). Aspirin 70-77 pro-platelet basic protein Homo sapiens 26-46 12781799-5 2003 Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal. Aspirin 0-7 pro-platelet basic protein Homo sapiens 258-265 16673274-3 2006 Inhibition of platelet cyclooxygenase-1 by aspirin is followed by relief of microvascular disturbances; correction of shortened platelet survival; correction of increased plasma beta-TG, PF4, and TM levels; and correction of increased TXB2 excretion to normal. Aspirin 43-50 pro-platelet basic protein Homo sapiens 178-185